2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
| العنوان: | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
|---|---|
| المؤلفون: | Sang Yong Kim, Soo Kyung Kim, Seung Hyun Ko, Kyong Soo Park, Sang Youl Rhee, Jae Hyeon Kim, Suk Chon, SungWan Chun, Eun Seok Kang, Bo-Yeon Kim, Seok O Park, Sung Hoon Yu, Dae Jung Kim, Jung Hyun Noh, Mee Kyoung Kim, Kang Woo Lee, Eun-Jung Rhee, Nan Hee Kim, Min Kyong Moon, Kyu Yeon Hur, Hyuk-Sang Kwon |
| المصدر: | Diabetes & Metabolism Journal, Vol 43, Iss 4, Pp 398-406 (2019) Diabetes & Metabolism Journal |
| بيانات النشر: | Korean Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, endocrine system diseases, diagnosis, Endocrinology, Diabetes and Metabolism, Population, 030209 endocrinology & metabolism, Review, 030204 cardiovascular system & hematology, Overweight, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Republic of Korea, Weight Loss, Prevalence, therapeutics, Humans, Hypoglycemic Agents, Medicine, Diabetic Nephropathies, In patient, Obesity, education, Intensive care medicine, Sodium-Glucose Transporter 2 Inhibitors, Clinical Care/Education, Antihypertensive Agents, Glycemic, education.field_of_study, lcsh:RC648-665, business.industry, practice guideline, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, medicine.disease, Clinical Practice, Blood pressure, diabetes mellitus, type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, medicine.symptom, business |
| الوصف: | The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. |
| تدمد: | 2233-6087 2233-6079 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f11e2bb07b556e490f92b3f0d9d7f5eTest https://doi.org/10.4093/dmj.2019.0137Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8f11e2bb07b556e490f92b3f0d9d7f5e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22336087 22336079 |
|---|